Research programme: labdane diterpene therapeutics - Medexis

Drug Profile

Research programme: labdane diterpene therapeutics - Medexis

Alternative Names: G200; Gerolab Project; Labdane diterpene therapeutics research programme - Medexis Biotech; MED-G200

Latest Information Update: 04 Feb 2011

Price : $50

At a glance

  • Originator Medexis
  • Class Diterpenes
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 06 Aug 2004 Preclinical trials in Cancer in Greece (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top